homeWelcome, sign in or click here to subscribe.login
     


 

 

Business


print  email to a friend  reprints add to mydjc  

November 20, 2024

Cancer Targeted Technology

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute awarded the Phase I portion ($400,000) of the fast track Phase I/II ($2.4 million) Small Business Innovation Research grant to develop a new drug to treat metastatic prostate cancer. The grant focuses on a promising new prodrug, CTT2274, that targets Prostate-Specific Membrane Antigen on prostate cancer and is designed to release a toxic drug, MMAE, within the cell that takes up the prodrug. In the Phase I portion of the grant, to be completed in Q2 2025, CTT will conduct additional non-clinical efficacy studies and manufacturing optimization. In Phase II of the grant, to be completed in Q2, 2026, CTT will conduct additional manufacturing and safety assessments necessary to advance CTT2274 to an Investigational New Drug application. These studies will support the initial clinical trial in metastatic prostate cancer planned for 2026.




Email or user name:
Password:
 
Forgot password? Click here.